Clinical Trial Update: Testing RG1-VLP Vaccine to Prevent HPV-related Cancers [Phase 1]

View source ↗

Summary

The National Cancer Institute is conducting a Phase 1 trial to evaluate the RG1-VLP vaccine for preventing HPV-related carcinomas, with recruitment currently on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus-related Carcinoma

Drugs mentioned

• RG1-VLP (RG1-VLP)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Human Papillomavirus-Related Carcinoma | Phase 1 | Status: RECRUITING